首页 | 本学科首页   官方微博 | 高级检索  
检索        


Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials
Authors:Kristian Reich  Craig Leonardi  Richard G Langley  Richard B Warren  Hervé Bachelez  Ricardo Romiti  Mamitaro Ohtsuki  Wen Xu  Nayan Acharya  Kathleen Solotkin  Jean-Frederic Colombel  Dana S Hardin
Institution:1. Dermatologikum Hamburg and SCIderm Research Institute, Hamburg, Germany;2. Department of Dermatology, Saint Louis University School of Medicine, Saint Louis, Missouri;3. Division of Clinical Dermatology and Cutaneous Science, Dallhousie University, Halifax, Nova Scotia, Canada;4. Dermatology Centre, Salford Royal Foundation Trust, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom;5. Sorbonne Paris Cité Université Paris Diderot, Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherché 1163, Imagine Institute, Necker Hospital, Paris, France;6. Department of Dermatology Hospital das Clínicas University of São Paulo, São Paulo, Brazil;7. Jichi Medical University, Shimotsuke, Japan;8. Eli Lilly and Company, Indianapolis, Indiana;9. Department of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York
Abstract:
Keywords:biologic therapy  Crohn's disease  inflammatory bowel disease  interleukin-17 antagonists  ixekizumab  psoriasis  ulcerative colitis  AE  adverse event  CD  Crohn's disease  EPIMAD  Registre Epidemiologique des Maladies de l'Appareil Digestif  IBD  inflammatory bowel disease  IL  interleukin  SAE  serious adverse event  TEAE  treatment-emergent adverse event  UC  ulcerative colitis
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号